<?xml version='1.0' encoding='utf-8'?>
<document id="25472557"><sentence text="Case report: Inability to achieve a therapeutic dose of tacrolimus in a pediatric allogeneic stem cell transplant patient after generic substitution."><entity charOffset="56-66" id="DDI-PubMed.25472557.s1.e0" text="tacrolimus" /></sentence><sentence text="Tacrolimus is an immunosuppressive drug that is used to lower the activity of the patient's immune system to prevent organ rejection" /><sentence text=" Unfortunately, there is limited data regarding the therapeutic equivalency of generic tacrolimus formulations especially in children"><entity charOffset="87-97" id="DDI-PubMed.25472557.s3.e0" text="tacrolimus" /></sentence><sentence text=" We report the case of a pediatric patient having an inability to achieve a therapeutic trough level for tacrolimus after conversion from brand name to the generic formulation" /><sentence text="" /><sentence text="A 17-month-old male patient diagnosed with T-cell acute lymphoblastic leukemia underwent allogeneic stem cell transplantation" /><sentence text=" The patient initially received intravenous (i" /><sentence text="v" /><sentence text=") tacrolimus for graft-versus-host disease (GVHD) prophylaxis and achieved therapeutic levels"><entity charOffset="2-12" id="DDI-PubMed.25472557.s9.e0" text="tacrolimus" /></sentence><sentence text=" The patient was then switched to an oral brand formulation of tacrolimus, and was able to maintain trough levels within the therapeutic range"><entity charOffset="63-73" id="DDI-PubMed.25472557.s10.e0" text="tacrolimus" /></sentence><sentence text=" After being discharged, the patient received the generic formulation of tacrolimus from an outside pharmacy and the care team was unable to reach therapeutic levels despite multiple dose escalations"><entity charOffset="73-83" id="DDI-PubMed.25472557.s11.e0" text="tacrolimus" /></sentence><sentence text=" Returning to brand name tacrolimus resulted in prompt achievement of therapeutic levels"><entity charOffset="25-35" id="DDI-PubMed.25472557.s12.e0" text="tacrolimus" /></sentence><sentence text="" /><sentence text="A likely etiology for the inability to achieve therapeutic trough levels in this patient is the change in formulation from brand formulation to generic version" /><sentence text=" Other factors including drug-drug interaction, preparation of the medication by a different pharmacy, drug-food interaction and genetic factors were also considered" /><sentence text=" Physicians and pharmacists must be aware of the inability to achieve targeted therapeutic concentrations of tacrolimus resulting from the conversion of brand name to the generic formulation until these generic formulations are tested in clinical trials in a pediatric population"><entity charOffset="109-119" id="DDI-PubMed.25472557.s16.e0" text="tacrolimus" /></sentence><sentence text="" /></document>